Respiratory Inhalation Portfolio (Generic)
Asthma, COPD
Key Facts
About Cipla
Cipla's mission is to ensure that no patient is denied access to high-quality, affordable medicine. A global leader with a market valuation exceeding $988 billion, the company has achieved this through pioneering complex generics, strategic international expansion, and a robust manufacturing footprint. Its core strategy leverages deep R&D in respiratory and oncology, vertical integration via API production, and a diversified geographic presence to drive sustainable growth and market leadership.
View full company profileTherapeutic Areas
Other Asthma, COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM9378 (SKB378/WIN378) | Harbour BioMed | Phase 1 |
| HP-Betadex DPI Formulations | Aquilon Pharmaceuticals | Clinical |
| Asthma vs. COPD Discrimination | The eNose Company | Clinical Development |
| Generic Advair (Fluticasone/Salmeterol) | Lupin Limited | ANDA Filed/Approved |
| Wixela Inhub (Fluticasone/Salmeterol) | Viatris | Launched |
| RELVAR/BREO ELLIPTA | Innoviva | Commercial |